SEC Form 4
Halozyme Therapeutics, Inc. (HALO) insider trading
In the 12 months to Oct 26, 2026, 5 HALO insiders reported open-market sales of $48.1M across 23 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $48.1M
- 23 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 22 of 23
- $46.1M of $48.1M sold (96%)
Who traded HALO, and when
- Sale
- Sale, pre-arranged (10b5-1)
HALO daily close from Oct 27, 2025 to Oct 26, 2026, between $61.63 and $127.22, last $127.22. 23 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Helen Torley, PRESIDENT AND CEO: sold $42.1M across 12 filings, first filed Nov 12, 2025, last Oct 8, 2026. Matthew L. Posard, Director: sold $2.6M across 2 filings, first filed Sep 17, 2026, last Oct 2, 2026. Cortney Caudill, SVP, CHIEF OPERATING OFFICER: sold $2.0M across 1 filing, first filed Mar 10, 2026, last Mar 10, 2026. Bernadette Connaughton, Director: sold $839.4K across 7 filings, first filed Nov 12, 2025, last Aug 11, 2026. Mahesh Krishnan, Director: sold $547.8K across 1 filing, first filed Jun 30, 2026, last Jun 30, 2026.
Largest mark · tap a row for others
Helen Torley · PRESIDENT AND CEO
Sale $6,610,501
60,000 shares at $110.18 avg
Filed Oct 8, 2026 · traded Oct 6
Pre-arranged (10b5-1) · close on filing date $109.84
Helen Torley · PRESIDENT AND CEO
PRESIDENT AND CEO
$42.1M soldMatthew L. Posard · Director
Director
$2.6M soldCortney Caudill · SVP, CHIEF OPERATING OFFICER
SVP, CHIEF OPERATING OFFICER
$2.0M soldBernadette Connaughton · Director
Director
$839.4K soldMahesh Krishnan · Director
Director
$547.8K soldOpen-market trades
23 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Helen Torley | PRESIDENT AND CEO | $42.1M | — | 12 | 100% of sales | |
| Matthew L. Posard | Director | $2.6M | — | 2 | 100% of sales | |
| Cortney Caudill | SVP, CHIEF OPERATING OFFICER | $2.0M | — | 1 | — | |
| Bernadette Connaughton | Director | $839.4K | — | 7 | 100% of sales | |
| Mahesh Krishnan | Director | $547.8K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 60,000 | $110.18 | $6.6M | 767,780 | |
traded | Matthew L. Posard Director | SalePre-arranged (10b5-1) | 5,230 | $108.54 | $567.7K | 54,809 | |
traded | Matthew L. Posard Director | SalePre-arranged (10b5-1) | 18,996 | $107.74 | $2.0M | 58,839 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 60,000 | $107.28 | $6.4M | 767,780 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 60,000 | $104.59 | $6.3M | 767,780 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 1,626 | $102.80 | $167.2K | 40,418 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 1,923 | $79.77 | $153.4K | 768,815 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 1,625 | $76.71 | $124.7K | 42,044 | |
traded | Mahesh Krishnan Director | SalePre-arranged (10b5-1) | 7,304 | $75.00 | $547.8K | 14,462 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 50,000 | $67.40 | $3.4M | 777,380 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 1,625 | $66.21 | $107.6K | 43,669 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 50,000 | $68.68 | $3.4M | 775,680 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 1,625 | $63.48 | $103.2K | 38,498 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 10,000 | $63.50 | $635.0K | 771,880 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 40,000 | $64.81 | $2.6M | 771,980 | |
traded | Cortney Caudill SVP, CHIEF OPERATING OFFICER | Sale | 28,857 | $67.75 | $2.0M | 7,055 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 50,000 | $69.52 | $3.5M | 770,451 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 50,000 | $77.07 | $3.9M | 708,719 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 2,000 | $70.25 | $140.5K | 40,123 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 16,569 | $68.92 | $1.1M | 708,980 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 829 | $71.60 | $59.4K | 42,123 | |
traded | Bernadette Connaughton Director | SalePre-arranged (10b5-1) | 2,000 | $68.48 | $137.0K | 42,952 | |
traded | Helen Torley PRESIDENT AND CEO | SalePre-arranged (10b5-1) | 60,000 | $69.47 | $4.2M | 741,001 |
GET /stocks/filings/vX/form-4?tickers=HALO&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"HALO",
"HTI"
],
"issuer_cik": "0001159036",
"owner_cik": "0001528185",
"accession_number": "0001159036-26-000140",
"form_type": "4",
"filing_date": "2026-10-08",
"period_of_report": "2026-10-06",
"issuer_name": "HALOZYME THERAPEUTICS, INC.",
"issuer_trading_symbol": "HALO",
"owner_name": "Torley Helen",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "PRESIDENT AND CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4810,
"transaction_price_per_share": 108.179,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 782970,
"transaction_value": 520340.99,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."
},
{
"id": "F10",
"description": "Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."
}
]
},
{
"tickers": [
"HALO",
"HTI"
],
"issuer_cik": "0001159036",
"owner_cik": "0001528185",
"accession_number": "0001159036-26-000140",
"form_type": "4",
"filing_date": "2026-10-08",
"period_of_report": "2026-10-06",
"issuer_name": "HALOZYME THERAPEUTICS, INC.",
"issuer_trading_symbol": "HALO",
"owner_name": "Torley Helen",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "PRESIDENT AND CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-06",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 6000,
"transaction_price_per_share": 109.334,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 779480,
"transaction_value": 656004,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."
},
{
"id": "F3",
"description": "Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 80 records
- Option exercises51 records
- Tax withholding18 records
- Tax withholding (sold to cover)1 record
- Grants and awards9 records
- Gifts1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Halozyme Therapeutics, Inc.'s CEO sold stock?
Yes. Helen Torley (CEO) sold 508,492 shares ($42.1M) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is HALO’s insider data?
These are HALO Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track HALO insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for HALO every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.